US$ 25.84
glp-1 receptor agonists for weight loss Mechanisms of Agonist-Induced Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation How GLP-1 Receptor Agonists Evolved
Description
B., Neogi, T., da Rocha Castelar-Pinheiro, G., Kapetanovic, M

have no competing interests

While there are limitations, the promise of improved diabetes management, cardiovascular benefits, and new formulations places GLP-1 agonists at the forefront of diabetes care

For patients with moderate, severe, and end-stage renal disease, a dosage adjustment is required (see Table 2 )

For example, medications like ACE inhibitors , ARBs , and beta-blockers generally do not interfere with the cardiovascular benefits of GLP-1 therapies

Dose adjustments or therapy changes based on response and tolerability
